{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:29:52Z","timestamp":1793345392828,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced metastasis produces cachexia, a complex skeletal muscle wasting syndrome that accounts for one-third of patient deaths. There is currently no approved drug therapy for cancer cachexia. Cancer-associated fibroblasts (CAF) within tumors have been hypothesized to contribute to cachexia, but the detailed mechanism(s) are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Myotubes were treated with conditioned media (CM) from CAF or CAF activated by cancer cells. Upregulated chemokines in the cancer-activated CAF CM were identified by cytokine array. The effects of chemokine neutralization were investigated using in vitro myotube cultures and in vivo mouse models. The mechanism of action was characterized by in vivo RNA Seq and validated in human muscle cells. Immunostaining delineated the chemokine expression pattern in a patient tumor type highly associated with cachexia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cancer-activated CAF induced myotube atrophy. CXCL5 was as the major chemokine highly upregulated in the cancer-activated CAF\n                      <jats:italic>.<\/jats:italic>\n                      CXCL5 treatment alone induced myotube atrophy and inhibited myogenic ERK1\/2 signaling, similar to cancer-activated CAF treatment. CXCL5 neutralization inhibited cachexia in mice co-injected with HCT 116 colon cancer cells and CAF. RNA Seq showed that CXCL5 neutralization upregulated hypertrophy-related PI3K-AKT-MyoG signaling and remodeled the muscle ECM. CXCL5 neutralization ameliorated muscle wasting induced by CXCL5 and IL-6 co-treatment, and also prevented atrophy in cancer-activated CAF CM-treated human myotubes. CAF were the major detectable source of CXCL5 in a patient tumor highly associated with cachexia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAF contribute to cachexia via cancer cell crosstalk that upregulates CXCL5 secretion. CXCL5 neutralization offers a novel therapeutic approach to maintain muscle mass in cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-025-01192-0","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:01:54Z","timestamp":1765756914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk"],"prefix":"10.1186","volume":"32","author":[{"given":"Hyun-Jun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Hwan","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Joon","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Woon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"1192_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1192_CR2","volume":"1","author":"T Miyawaki","year":"2020","unstructured":"Miyawaki T, et al. Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC. JTO Clin Res Rep. 2020;1(2):100020.","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"1192_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5(2):e200.","journal-title":"Oncogenesis"},{"issue":"1","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","volume":"1","author":"S von Haehling","year":"2010","unstructured":"von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1(1):1\u20135.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jcsm.12475","volume":"10","author":"R Tomasin","year":"2019","unstructured":"Tomasin R, Martin A, Cominetti MR. Metastasis and cachexia: alongside in clinics, but not so in animal models. J Cachexia Sarcopenia Muscle. 2019;10(6):1183\u201394.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/annonc\/mdu086","volume":"25","author":"D Blum","year":"2014","unstructured":"Blum D, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model\u2013a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol. 2014;25(8):1635\u201342.","journal-title":"Ann Oncol"},{"issue":"2","key":"1192_CR7","first-page":"72","volume":"52","author":"A Inui","year":"2002","unstructured":"Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52(2):72\u201391.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1192_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky043","volume":"2","author":"SM Judge","year":"2018","unstructured":"Judge SM, et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. JNCI Cancer Spectr. 2018;2(3):pky043.","journal-title":"JNCI Cancer Spectr"},{"key":"1192_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1651","volume":"361","author":"CA Celis-Morales","year":"2018","unstructured":"Celis-Morales CA, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651.","journal-title":"BMJ"},{"issue":"2","key":"1192_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809910","volume":"12","author":"SG Liva","year":"2020","unstructured":"Liva SG, et al. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol Med. 2020;12(2):e9910.","journal-title":"EMBO Mol Med"},{"key":"1192_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041565","author":"A Kasprzak","year":"2021","unstructured":"Kasprzak A. The role of tumor microenvironment cells in colorectal cancer (CRC) cachexia. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22041565.","journal-title":"Int J Mol Sci"},{"key":"1192_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.597675","volume":"11","author":"JM Webster","year":"2020","unstructured":"Webster JM, et al. Inflammation and skeletal muscle wasting during cachexia. Front Physiol. 2020;11:597675.","journal-title":"Front Physiol"},{"issue":"6","key":"1192_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/jcsm.12626","volume":"11","author":"P Morigny","year":"2020","unstructured":"Morigny P, et al. High levels of modified ceramides are a defining feature of murine and human cancer cachexia. J Cachexia Sarcopenia Muscle. 2020;11(6):1459\u201375.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1192_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells12222598","author":"AL Marzan","year":"2023","unstructured":"Marzan AL, Chitti SV. Unravelling the role of cancer cell-derived extracellular vesicles in muscle atrophy, lipolysis, and cancer-associated cachexia. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12222598.","journal-title":"Cells"},{"issue":"6","key":"1192_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.devcel.2010.05.012","volume":"18","author":"M Egeblad","year":"2010","unstructured":"Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6):884\u2013901.","journal-title":"Dev Cell"},{"key":"1192_CR16","doi-asserted-by":"crossref","unstructured":"Bagley RG. The Tumor Microenvironment. Cancer Drug Discovery and Development (CDD&D). New York, NY: Humana; 2010.","DOI":"10.1007\/978-1-4419-6615-5"},{"issue":"2","key":"1192_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ijc.25060","volume":"127","author":"DW Jung","year":"2010","unstructured":"Jung DW, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer. 2010;127(2):332\u201344.","journal-title":"Int J Cancer"},{"issue":"8","key":"1192_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.251","volume":"10","author":"JH Lee","year":"2020","unstructured":"Lee JH, et al. Inhibited inositol monophosphatase and decreased myo-inositol concentration improve wasting in skeletal muscles. Clin Transl Med. 2020;10(8):e251.","journal-title":"Clin Transl Med"},{"issue":"6","key":"1192_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/s44321-025-00234-2","volume":"17","author":"SH Lee","year":"2025","unstructured":"Lee SH, et al. Modulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression. EMBO Mol Med. 2025;17(6):1259\u201388.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41591-018-0131-6","volume":"24","author":"C Vinel","year":"2018","unstructured":"Vinel C, et al. The exerkine apelin reverses age-associated sarcopenia. Nat Med. 2018;24(9):1360\u201371.","journal-title":"Nat Med"},{"issue":"1","key":"1192_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-023-01900-w","volume":"22","author":"C Chen","year":"2023","unstructured":"Chen C, et al. Cxcl5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus. Cardiovasc Diabetol. 2023;22(1):172.","journal-title":"Cardiovasc Diabetol"},{"key":"1192_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.984459","volume":"12","author":"Q Wan","year":"2022","unstructured":"Wan Q, et al. Prognostic value of cachexia index in patients with colorectal cancer: a retrospective study. Front Oncol. 2022;12:984459.","journal-title":"Front Oncol"},{"key":"1192_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semcancer.2016.01.002","volume":"36","author":"A Sukari","year":"2016","unstructured":"Sukari A, et al. F-box proteins in cancer cachexia and muscle wasting: emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016;36:95\u2013104.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1192_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321\u20137.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1192_CR25","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1038\/ncomms5282","volume":"5","author":"Z Huang","year":"2014","unstructured":"Huang Z, et al. The stem cell factor\/Kit signalling pathway regulates mitochondrial function and energy expenditure. Nat Commun. 2014;5:4282.","journal-title":"Nat Commun"},{"issue":"12","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s11999-012-2456-7","volume":"470","author":"SP Frey","year":"2012","unstructured":"Frey SP, et al. VEGF improves skeletal muscle regeneration after acute trauma and reconstruction of the limb in a rabbit model. Clin Orthop Relat Res. 2012;470(12):3607\u201314.","journal-title":"Clin Orthop Relat Res"},{"issue":"7","key":"1192_CR27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1128\/MCB.01071-14","volume":"35","author":"B Seaberg","year":"2015","unstructured":"Seaberg B, et al. Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions. Mol Cell Biol. 2015;35(7):1238\u201353.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"1192_CR28","doi-asserted-by":"publisher","first-page":"C1040","DOI":"10.1152\/ajpcell.00475.2008","volume":"296","author":"H Shi","year":"2009","unstructured":"Shi H, et al. Mitogen-activated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. Am J Physiol Cell Physiol. 2009;296(5):C1040\u20138.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41389-020-00249-z","volume":"9","author":"Z Mao","year":"2020","unstructured":"Mao Z, et al. Cxcl5 promotes gastric cancer metastasis by inducing epithelial-mesenchymal transition and activating neutrophils. Oncogenesis. 2020;9(7):63.","journal-title":"Oncogenesis"},{"issue":"1","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2023.09.003","volume":"30","author":"G Lazennec","year":"2024","unstructured":"Lazennec G, Rajarathnam K, Richmond A. CXCR2 chemokine receptor - a master regulator in cancer and physiology. Trends Mol Med. 2024;30(1):37\u201355.","journal-title":"Trends Mol Med"},{"issue":"1","key":"1192_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"key":"1192_CR32","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.043166","author":"JR Huot","year":"2020","unstructured":"Huot JR, et al. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. Dis Model Mech. 2020. https:\/\/doi.org\/10.1242\/dmm.043166.","journal-title":"Dis Model Mech"},{"issue":"10","key":"1192_CR33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.biocel.2013.05.016","volume":"45","author":"S Ciciliot","year":"2013","unstructured":"Ciciliot S, et al. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013;45(10):2191\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"1192_CR34","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1172\/JCI68523","volume":"123","author":"WA He","year":"2013","unstructured":"He WA, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. 2013;123(11):4821\u201335.","journal-title":"J Clin Invest"},{"issue":"1","key":"1192_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10974-023-09663-3","volume":"45","author":"SL Chen","year":"2024","unstructured":"Chen SL, et al. Post-transcriptional regulation of myogenic transcription factors during muscle development and pathogenesis. J Muscle Res Cell Motil. 2024;45(1):21\u201339.","journal-title":"J Muscle Res Cell Motil"},{"issue":"5","key":"1192_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/jcsm.12354","volume":"9","author":"JL Brown","year":"2018","unstructured":"Brown JL, et al. Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2018;9(5):987\u20131002.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"1192_CR37","doi-asserted-by":"publisher","first-page":"E866","DOI":"10.1152\/ajpendo.00104.2009","volume":"297","author":"T Nedachi","year":"2009","unstructured":"Nedachi T, et al. Characterization of contraction-inducible CXC chemokines and their roles in C2C12 myocytes. Am J Physiol Endocrinol Metab. 2009;297(4):E866\u201378.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fgene.2020.00541","volume":"11","author":"GJ Fernandez","year":"2020","unstructured":"Fernandez GJ, et al. Microrna-mrna co-sequencing identifies transcriptional and post-transcriptional regulatory networks underlying muscle wasting in cancer cachexia. Front Genet. 2020;11:541.","journal-title":"Front Genet"},{"issue":"4","key":"1192_CR39","first-page":"E720","volume":"273","author":"SJ Wigmore","year":"1997","unstructured":"Wigmore SJ, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273(4):E720\u20136.","journal-title":"Am J Physiol"},{"issue":"10","key":"1192_CR40","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1182\/blood.V95.10.3032","volume":"95","author":"C Murdoch","year":"2000","unstructured":"Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000;95(10):3032\u201343.","journal-title":"Blood"},{"issue":"1","key":"1192_CR41","doi-asserted-by":"publisher","first-page":"14910","DOI":"10.1038\/s41598-019-51410-7","volume":"9","author":"MO Baek","year":"2019","unstructured":"Baek MO, et al. Simulated microgravity inhibits C2C12 myogenesis via phospholipase D2-induced Akt\/FOXO1 regulation. Sci Rep. 2019;9(1):14910.","journal-title":"Sci Rep"},{"issue":"3","key":"1192_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.26993","volume":"62","author":"N Senoo","year":"2020","unstructured":"Senoo N, et al. Glycerophospholipid profile alterations are associated with murine muscle-wasting phenotype. Muscle Nerve. 2020;62(3):413\u20138.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1192_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jcsm.12695","volume":"12","author":"CP Lambert","year":"2021","unstructured":"Lambert CP. Should the FDA\u2019s criteria for the clinical efficacy of cachexia drugs be changed? Is Ostarine safe and effective? J Cachexia Sarcopenia Muscle. 2021;12(3):531\u20132.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1192_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1152\/japplphysiol.00196.2023","volume":"135","author":"AR Cabrera","year":"2023","unstructured":"Cabrera AR, et al. Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia. J Appl Physiol (1985). 2023;135(3):655\u201372.","journal-title":"J Appl Physiol (1985)"},{"issue":"6","key":"1192_CR45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11914-020-00628-w","volume":"18","author":"X Zhong","year":"2020","unstructured":"Zhong X, Zimmers TA. Sex differences in cancer cachexia. Curr Osteoporos Rep. 2020;18(6):646\u201354.","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"1192_CR46","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ajpath.2010.11.058","volume":"178","author":"A Li","year":"2011","unstructured":"Li A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011;178(3):1340\u20139.","journal-title":"Am J Pathol"},{"key":"1192_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/bs.mcb.2023.06.002","volume":"183","author":"MF Baietti","year":"2024","unstructured":"Baietti MF, Leucci E. Humanized mouse models for anti-cancer therapy. Methods Cell Biol. 2024;183:317\u201333.","journal-title":"Methods Cell Biol"},{"key":"1192_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2020.08.035","volume":"493","author":"L Qi","year":"2020","unstructured":"Qi L, et al. Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. Cancer Lett. 2020;493:197\u2013206.","journal-title":"Cancer Lett"},{"issue":"1","key":"1192_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13293-022-00451-1","volume":"13","author":"B Smarr","year":"2022","unstructured":"Smarr B, Kriegsfeld LJ. Female mice exhibit less overall variance, with a higher proportion of structured variance, than males at multiple timescales of continuous body temperature and locomotive activity records. Biol Sex Differ. 2022;13(1):41.","journal-title":"Biol Sex Differ"},{"issue":"6","key":"1192_CR50","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.21873\/anticanres.14312","volume":"40","author":"KB Bae","year":"2020","unstructured":"Bae KB, et al. An animal model of colorectal cancer liver metastasis with a high metastasis rate and clonal dynamics. Anticancer Res. 2020;40(6):3297\u2013306.","journal-title":"Anticancer Res"},{"issue":"1","key":"1192_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40246-024-00635-3","volume":"18","author":"O Aladelokun","year":"2024","unstructured":"Aladelokun O, et al. Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex. Hum Genomics. 2024;18(1):67.","journal-title":"Hum Genomics"},{"key":"1192_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00720","volume":"10","author":"BR Counts","year":"2019","unstructured":"Counts BR, et al. The effect of estradiol administration on muscle mass loss and cachexia progression in female Apc (Min\/+) mice. Front Endocrinol (Lausanne). 2019;10:720.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1192_CR53","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1152\/ajpendo.00294.2016","volume":"312","author":"KL Hetzler","year":"2017","unstructured":"Hetzler KL, et al. Ovarian function\u2019s role during cancer cachexia progression in the female mouse. Am J Physiol Endocrinol Metab. 2017;312(5):E447\u201359.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"1192_CR54","first-page":"2909","volume":"41","author":"T Banh","year":"2019","unstructured":"Banh T, et al. Higher tumor mass and lower adipose mass are associated with colon-26 adenocarcinoma-induced cachexia in male, female and ovariectomized mice. Oncol Rep. 2019;41(5):2909\u201318.","journal-title":"Oncol Rep"},{"issue":"3","key":"1192_CR55","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jcsm.12706","volume":"12","author":"CS Deane","year":"2021","unstructured":"Deane CS, et al. Transcriptomic meta-analysis of disuse muscle atrophy vs. resistance exercise-induced hypertrophy in young and older humans. J Cachexia Sarcopenia Muscle. 2021;12(3):629\u201345.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1192_CR56","first-page":"267","volume":"346","author":"DJ Glass","year":"2010","unstructured":"Glass DJ. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol. 2010;346:267\u201378.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1192_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091970","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9091970.","journal-title":"Cells"},{"issue":"2","key":"1192_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/etm.2020.9608","volume":"21","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, et al. BAY11-7082 inhibits the expression of tissue factor and plasminogen activator inhibitor-1 in type-II alveolar epithelial cells following TNF-alpha stimulation via the NF-kappaB pathway. Exp Ther Med. 2021;21(2):177.","journal-title":"Exp Ther Med"},{"issue":"6","key":"1192_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039945","volume":"7","author":"AR Hussain","year":"2012","unstructured":"Hussain AR, et al. Cross-talk between NFkB and the PI3-kinase\/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS ONE. 2012;7(6):e39945.","journal-title":"PLoS ONE"},{"issue":"51","key":"1192_CR60","doi-asserted-by":"publisher","first-page":"30269","DOI":"10.1074\/jbc.M115.685164","volume":"290","author":"D Lee","year":"2015","unstructured":"Lee D, Goldberg AL. Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT\/mechanistic target of rapamycin (mTOR) by the protein acetylase, GCN5. J Biol Chem. 2015;290(51):30269\u201379.","journal-title":"J Biol Chem"},{"issue":"21","key":"1192_CR61","doi-asserted-by":"publisher","first-page":"17737","DOI":"10.1074\/jbc.M111.291708","volume":"287","author":"Z Li","year":"2012","unstructured":"Li Z, et al. Forkhead transcription factor FOXO3a protein activates nuclear factor kappaB through B-cell lymphoma\/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation. J Biol Chem. 2012;287(21):17737\u201345.","journal-title":"J Biol Chem"},{"key":"1192_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.semcdb.2017.11.010","volume":"72","author":"JM Hernandez-Hernandez","year":"2017","unstructured":"Hernandez-Hernandez JM, et al. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. Semin Cell Dev Biol. 2017;72:10\u20138.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"1192_CR63","first-page":"266","volume":"12","author":"JJ Schwarz","year":"1992","unstructured":"Schwarz JJ, et al. The basic region of myogenin cooperates with two transcription activation domains to induce muscle-specific transcription. Mol Cell Biol. 1992;12(1):266\u201375.","journal-title":"Mol Cell Biol"},{"key":"1192_CR64","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60445","author":"M Ganassi","year":"2020","unstructured":"Ganassi M, et al. Myogenin is an essential regulator of adult myofibre growth and muscle stem cell homeostasis. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.60445.","journal-title":"Elife"},{"issue":"47","key":"1192_CR65","doi-asserted-by":"publisher","first-page":"36750","DOI":"10.1074\/jbc.M005030200","volume":"275","author":"Q Xu","year":"2000","unstructured":"Xu Q, Wu Z. The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem. 2000;275(47):36750\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"1192_CR66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1152\/japplphysiol.00897.2017","volume":"124","author":"BN VanderVeen","year":"2018","unstructured":"VanderVeen BN, et al. Skeletal muscle function during the progression of cancer cachexia in the male Apc(Min\/+) mouse. J Appl Physiol (1985). 2018;124(3):684\u201395.","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"1192_CR67","first-page":"247","volume":"15","author":"X Cheng","year":"2018","unstructured":"Cheng X, et al. Morphological and molecular comparisons between tibialis anterior muscle and levator veli palatini muscle: a preliminary study on their augmentation potential. Exp Ther Med. 2018;15(1):247\u201353.","journal-title":"Exp Ther Med"},{"issue":"7","key":"1192_CR68","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/ijc.32278","volume":"145","author":"Z Li","year":"2019","unstructured":"Li Z, et al. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. Int J Cancer. 2019;145(7):1946\u201357.","journal-title":"Int J Cancer"},{"key":"1192_CR69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12935-018-0562-7","volume":"18","author":"B Hu","year":"2018","unstructured":"Hu B, et al. Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int. 2018;18:68.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"1192_CR70","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.7150\/jca.40517","volume":"11","author":"R Zhang","year":"2020","unstructured":"Zhang R, et al. Cxcl5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer. 2020;11(9):2371\u201381.","journal-title":"J Cancer"},{"issue":"14","key":"1192_CR71","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.ejca.2011.11.032","volume":"48","author":"M Kawamura","year":"2012","unstructured":"Kawamura M, et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012;48(14):2244\u201351.","journal-title":"Eur J Cancer"},{"key":"1192_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944494","volume":"12","author":"J Deng","year":"2022","unstructured":"Deng J, et al. CXCL5: a coachman to drive cancer progression. Front Oncol. 2022;12:944494.","journal-title":"Front Oncol"},{"issue":"2\u20133","key":"1192_CR73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cac2.12010","volume":"40","author":"W Zhang","year":"2020","unstructured":"Zhang W, et al. CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun. 2020;40(2\u20133):69\u201380.","journal-title":"Cancer Commun"},{"issue":"3","key":"1192_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41419-019-1431-6","volume":"10","author":"C Chen","year":"2019","unstructured":"Chen C, et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT\/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019;10(3):178.","journal-title":"Cell Death Dis"},{"issue":"237","key":"1192_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1192_CR76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/apm.2018.12.01","volume":"8","author":"VE Baracos","year":"2019","unstructured":"Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 2019;8(1):3\u201312.","journal-title":"Ann Palliat Med"},{"issue":"5","key":"1192_CR77","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01192-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:01:57Z","timestamp":1765756917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-025-01192-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01192-0","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supplied by the Chonnam medical school, Gwangju, Republic of Korea (Institutional Review Board approval number: CNUHH-2021\u2013217).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}